Compare BFLY & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFLY | CDNA |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2020 | 2007 |
| Metric | BFLY | CDNA |
|---|---|---|
| Price | $9.07 | $68.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $11.40 | ★ $58.83 |
| AVG Volume (30 Days) | ★ 5.3M | 1.2M |
| Earning Date | 10-30-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.82 | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | ★ $97,610,000.00 | $48,324,000.00 |
| Revenue This Year | $24.74 | $30.36 |
| Revenue Next Year | $23.94 | $6.23 |
| P/E Ratio | ★ N/A | $31.09 |
| Revenue Growth | ★ 18.96 | 18.93 |
| 52 Week Low | $1.90 | $13.95 |
| 52 Week High | $10.05 | $67.29 |
| Indicator | BFLY | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.89 | 82.71 |
| Support Level | $3.57 | $17.26 |
| Resistance Level | $9.79 | N/A |
| Average True Range (ATR) | 0.69 | 3.09 |
| MACD | 0.07 | 1.06 |
| Stochastic Oscillator | 68.15 | 97.48 |
Butterfly Network Inc is a digital health business transforming care with handheld, whole-body ultrasound. Powered by its proprietary Ultrasound-on-Chip technology, its solution enables the acquisition of imaging information from an affordable, powerful device that fits in a healthcare professional's pocket with a combination of cloud-connected software and hardware technology that is easily accessed through a mobile application. Butterfly iQ+ is an ultrasound device that can perform whole-body imaging in a single handheld probe using semiconductor technology. The company operates in one reportable segment, which includes all activities related to the development, manufacture, and sale of the Company's products, software, and other services.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.